Anika Therapeutics, Inc. Stock News

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options

Anika Therapeutics is an HA-platform company with regenerative, OA pain, and non-orthopedic products. Their main line is called Integrity. But Hyalofast and Cingal can also eventually target the sizeable cartilage and OA markets. ANIK's Integrity outperformed since launch, and their regenerative solutions have grown YoY. That's why the company believes it can also tap into the tendon-augmentati...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether Anika and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

Anika Therapeutics (ANIK -27.42%), a medical technology company focused on joint preservation and regenerative therapy products, released its earnings on July 30, 2025. The key news from the release was that while the company outperformed revenue estimates—reporting $28.2 million (GAAP) compared to the expected $27.03 million—profitability came under pressure, with a larger loss versus last year.

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Cheryl Renee Blanchard - President, CEO & Director Matt Hall - Corporate Participant Stephen D. Griffin - Executive VP, CFO & COO Conference Call Participants Anderson Schock - B.

Regenerative Solutions revenue up 41% with Integrity ™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function